Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | APAF1 | O14727 | 1/20 | 0.55 |
| ▸ | ACP3 | P15309 | 2/20 | 0.53 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.51 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.51 |
| ▸ | LMNA | P02545 | 1/20 | 0.51 |
| ▸ | HPGD | P15428 | 1/20 | 0.51 |
| ▸ | MMP9 | P14780 | 1/20 | 0.49 |
| ▸ | MMP8 | P22894 | 1/20 | 0.49 |
| ▸ | MEN1 | O00255 | 1/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.49 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.48 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.46 |
| ▸ | SRC | P12931 | 1/20 | 0.46 |
| ▸ | MME | P08473 | 2/20 | 0.46 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.46 |
| ▸ | POLB | P06746 | 1/20 | 0.46 |
| ▸ | CTDSP1 | Q9GZU7 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18722284 | 1.00 | APAF1 (0.55) | APAF1ACP3HSD17B10KDM4EALDH1A1 | |
| SCHEMBL6809827 | 1.00 | APAF1 (0.55) | APAF1ACP3HSD17B10KDM4EALDH1A1 | |
| SCHEMBL6155794 | 1.00 | APAF1 (0.55) | APAF1ACP3HSD17B10KDM4EALDH1A1 | |
| SCHEMBL3823989 | 1.00 | APAF1 (0.55) | APAF1ACP3HSD17B10KDM4EALDH1A1 | |
| SCHEMBL5513822 | 0.84 | ACP3 (0.50) | APAF1ACP3HSD17B10KDM4EALDH1A1 | |
| SCHEMBL7365794 | 0.84 | ACP3 (0.50) | APAF1ACP3HSD17B10KDM4EALDH1A1 | |
| SCHEMBL7342569 | 0.83 | APAF1 (0.55) | APAF1ACP3HSD17B10KDM4EALDH1A1 | |
| SCHEMBL8766752 | 0.83 | LMNA (0.49) | APAF1HSD17B10KDM4EALDH1A1LMNA | |
| SCHEMBL7890911 | 0.83 | LMNA (0.49) | APAF1HSD17B10KDM4EALDH1A1LMNA | |
| SCHEMBL9574986 | 0.83 | LMNA (0.49) | APAF1HSD17B10KDM4EALDH1A1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100189819-A1 | NEURO-DEGENERATIVE INHIBITOR, NEURO-ENDOCRINE MODULATOR, AND NEURO-CEREBRAL METABOLISM ENHANCER | INTRATHERAPIES LLC (US) | 2010-07-29 | — | — | US | claimed |
| WO-2004032916-A1 | A COMPOSITION COMPRISING SELEGELINE, PROCAINE, VINPOCETINE, TRIMETHYLGLYCINEAN AND A N-GABA INGREDIENT FOR TREATING NEURODEGENERATIVE DISORDERS | UNIFUND CORPORATION LIMITED (GB) | 2004-04-22 | — | — | WO | claimed |
| US-20040067986-A1 | Neuro-degenerative inhibitor, neuro-endocrine modulator, and neuro-cerebral metabolism enhancer | UNIFUND CORPORATION | 2004-04-08 | — | — | US | claimed |
| EP-2736895-A1 | 2 - (2, 4, 5 - SUBSTITUTED -ANILINO) PYRIMIDINE DERIVATIVES AS EGFR MODULATORS USEFUL FOR TREATING CANCER | Astrazeneca AB (SE) | 2014-06-04 | — | — | EP | disclosed |
| WO-2013014448-A1 | 2 - (2, 4, 5 - SUBSTITUTED -ANILINO) PYRIMIDINE DERIVATIVES AS EGFR MODULATORS USEFUL FOR TREATING CANCER | ASTRAZENECA AB (SE) | 2013-01-31 | — | — | WO | disclosed |
| EP-2366704-A1 | Inhibitors of serine proteases | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2011-09-21 | — | — | EP | disclosed |
| US-20100189819-A1 | NEURO-DEGENERATIVE INHIBITOR, NEURO-ENDOCRINE MODULATOR, AND NEURO-CEREBRAL METABOLISM ENHANCER | INTRATHERAPIES LLC (US) | 2010-07-29 | — | — | US | disclosed |
| EP-0987332-B1 | DNA encoding a polypeptide having stereoselective transaminase activity, and transformants comprising said DNA | KANEKA CORP (JP) | 2009-08-19 | — | — | EP | disclosed |
| US-7169592-B2 | Producing optically active amino compounds | KANEKA CORPORATION (JP) | 2007-01-30 | — | — | US | disclosed |
| EP-0857790-B1 | PROCESS FOR PRODUCING OPTICALLY ACTIVE AMINO COMPOUNDS | KANEKA CORP (JP) | 2005-08-17 | — | — | EP | disclosed |
| WO-2004032916-A1 | A COMPOSITION COMPRISING SELEGELINE, PROCAINE, VINPOCETINE, TRIMETHYLGLYCINEAN AND A N-GABA INGREDIENT FOR TREATING NEURODEGENERATIVE DISORDERS | UNIFUND CORPORATION LIMITED (GB) | 2004-04-22 | — | — | WO | disclosed |
| US-20010031487-A1 | Process for producing optically active amino compounds | KANEKA CORPORATION | 2001-10-18 | — | — | US | disclosed |
| WO-2001060813-A1 | BETA-ALANINE DERIVATIVES AND THEIR USE AS RECEPTOR ANTAGONISTS | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2001-08-23 | — | — | WO | disclosed |
| US-6221638-B1 | BY STEREOSELECTIVELY CARRYING OUT AMINO GROUP TRANSFER BY ACTION OF AN (R)-FORM-SPECIFIC TRANSAMINASE IN THE CO-PRESENCE OF A KETONE (AMINO ACCEPTOR) AND AMINO COMPOUND (AMINO DONOR); YIELDS AMINO COMPOUNDS HAIVNG ARYL GROUP AT THE 1-POSITION | KANEKA CORPORATION (JP) | 2001-04-24 | — | — | US | disclosed |
| EP-0987332-A1 | PROCESS FOR PRODUCING OPTICALLY ACTIVE AMINO COMPOUNDS | Kaneka Corporation (JP) | 2000-03-22 | — | — | EP | disclosed |
| EP-0925303-A1 | PHOSPHINIC ACID AMIDES AS MATRIX METALLOPROTEASE INHIBITORS | THE PROCTER & GAMBLE COMPANY (US) | 1999-06-30 | — | — | EP | disclosed |
| US-5830915-A | ORAL DISEASES; SKIN DISORDERS; ANTIINFLAMMATORY AGENTS | THE PROCTER & GAMBLE COMPANY (US) | 1998-11-03 | — | — | US | disclosed |
| EP-0857790-A1 | PROCESS FOR PRODUCING OPTICALLY ACTIVE AMINO COMPOUNDS | KANEKA CORPORATION (JP) | 1998-08-12 | — | — | EP | disclosed |
| WO-1998008853-A9 | PHOSPHINIC ACID AMIDES AS MATRIX METALLOPROTEASE INHIBITORS | — | 1998-08-06 | — | — | WO | disclosed |
| WO-1998008853-A1 | PHOSPHINIC ACID AMIDES AS MATRIX METALLOPROTEASE INHIBITORS | THE PROCTER & GAMBLE COMPANY (US) | 1998-03-05 | — | — | WO | disclosed |